《盈喜》中國儒意(00136.HK)料中期扭虧 賺10億至12億人民幣
中國儒意(00136.HK)發盈喜,預料截至2025年6月30日止中期將實現扭虧爲盈,錄得未經審計除稅後綜合淨利潤約10億至12億元人民幣(下同),對比去年同期錄除稅後淨虧損約1.23億元;收入預期介乎約21億至23億元,較2024年同期的約18.4億元增長14%至25%。公司解釋,業績改善主要受益於整體業務穩健增長及協同效應持續釋放,變現效率提升,帶動收入與利潤增長,以及2021年收購Virtual Cinema Entertainment Limited所形成的或然應付對價公允價值變動影響消除。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.